Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

about

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.

P2860

Q37375259-1E4F3368-39BA-419C-B6EB-828629394B17 Q38820085-3FD46E1F-C530-4F61-B872-0CE06AD4C6D4

P2860

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

Item

http://www.wikidata.org/entity/Q38465861

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

@en

type

Item

label

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

@en

prefLabel

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

@en

P1476

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

@en

P2093

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Paolo Antonio Ascierto

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Basal-cell carcinoma.

Hedgehog signaling: networking to nurture a promalignant tumor microenvironment.

Assessing current treatment options for patients with severe/advanced basal cell carcinoma.

Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.

Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

P304

1429-1435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.20

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ketty Peris

Lisa Licitra

Piergiacomo Calzavara-Pinton

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25952787

http://www.w3.org/2001/XMLSchema#string

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

about

P2860

P2860

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698